194785-39-2

Upstream product

• 501-53-1 benzyl chloroformate 
• 85951-60-6 (-)-7-OH-AT 
• 231623-76-0 N-[(2S)-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]benzamide 
• 231623-74-8 N-(7-methoxy-3,4-dihydro-naphthalen-2-yl)-benzamide 
• 4133-34-0 7-methoxyl-2-tetralone 
• 603122-70-9 (7S)-7-(benzylamino)-5,6,7,8-tetrahydronaphthalen-2-ol 
• 132990-84-2 (2S)-N-benzyl-7-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine 

Downstream Products

• 379222-83-0 (2S)-2-benzyloxycarbonylamino-7-trifluoromethanesulfonate-tetralin 
• 603123-92-8 4-((7S)-7-{[(2R)-2-hydroxy-2-(4-methylphenyl)ethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoic acid hydrochloride 
• 603124-15-8 C₃₁H₃₅NO₅ 
• 603122-43-6 C₂₅H₂₅ClN₂O₃ 
• 603123-97-3 C₂₉H₃₂N₂O₆ 
• 603122-50-5 4-((7S)-7-{(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-(3-pyridinyl)ethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoic acid 
• 603122-48-1 C₂₉H₃₁ClN₂O₅ 
• 603122-47-0 methyl 4-((7S)-7-{(tert-butoxycarbonyl)[(2R)-2-(6-chloro-3-pyridinyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphtahlenyl)benzoate 
• 603123-08-6 methyl 4-[(7S)-7-{(tert-butoxycarbonyl)[(2R)-2-hydroxy-2-(4-methylphenyl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-2-yl]benzoate 
• 603124-73-8 sodium 4-((7S)-7-{[(2R)-2-(6-chloro-3-pyridinyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoate 
• 603125-45-7 sodium 4-((7S)-7-{[(2R)-2-(3,4-dichlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoate 
• 603125-43-5 sodium 4-((7S)-7-{[(2R)-2-(4-trifluoromethylphenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoate 
• 603125-44-6 sodium 4-((7S)-7-{[(2R)-2-(4-cyanophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoate 
• 603125-42-4 sodium 4-((7S)-7-{[(2R)-2-(2-chlorophenyl)-2-hydroxyethyl]amino}-5,6,7,8-tetrahydro-2-naphthalenyl)benzoate 

Relevant academic research and scientific papers

Discovery of a novel series of benzoic acid derivatives as potent and selective human β3 adrenergic receptor agonists with good oral bioavailability. 3. Phenylethanolaminotetraline (PEAT) skeleton containing biphenyl or biphenyl ether moiety

We designed a series of benzoic acid derivatives containing the biphenyl ether or biphenyl template on the RHS and a phenylethanolaminotetraline (PEAT) skeleton, which was prepared by highly stereoselective synthesis, to generate two structurally different lead compounds (10c, 10m) with a good balance of potency, selectivity, and pharmacokinetic profile. Further optimization of the two lead compounds to improve potency led to several potential candidates (i.e., 11f, 11l, 11o, 12b). In particular, biphenyl analogue 12b exhibited an excellent balance of high potency (EC50 = 0.38 nM) for β3, high selectivity over β1 and β2, and good pharmacokinetic properties in rats, dogs, and monkeys.